AIDS Treatment Composition Using Ganoderma and Cordyceps
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for AIDS, including HAART, face challenges such as limited drug combinations, compliance issues, toxicity, and high costs, with no effective vaccine available, necessitating the exploration of alternative therapeutic approaches.
Innovation Solution
A composition comprising Ganoderma, Radix Panacis Quinquefolii or Radix Et Rhizoma Ginseng, fermented Cordyceps sinensis powder, and/or Cordyceps, combined with additional herbs like Flos Rosae Rugosae, Radix Pseudostellariae, Radix Codonopsis, and Radix Astragali, which are processed into various dosage forms to create a treatment for AIDS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HAART (Highly Active Antiretroviral Therapy) is used to treat AIDS, then the morbidity and mortality rate of AIDS is significantly decreased, but the therapy involves expensive drugs that are far beyond what an ordinary patient can afford
Solution Approach 1:
The patent combines multiple traditional Chinese medicine ingredients (Ganoderma, Cordyceps sinensis, Radix Panacis Quinquefolii, Radix Et Rhizoma Ginseng, and other auxiliary herbs) into a composite formulation. This composite approach integrates the therapeutic effects of individual herbs to achieve antiviral and immunomodulatory activities comparable to HAART, while using more affordable natural materials.
Solution Approach 2:
The patent specifies precise dosage ranges for each ingredient (e.g., Ganoderma: 5-200 parts, Cordyceps sinensis powder: 1-90 parts) to optimize therapeutic effectiveness. By controlling the parameters of ingredient proportions and processing methods, the formulation achieves reliable antiviral effects at lower cost.
2Reliability
If HAART (cocktail therapy) is used to treat AIDS, then the morbidity and mortality rate is decreased, but the development of combinational use of drugs is greatly limited due to compliance, toxicity, and drug resistance issues
Solution Approach 1:
The patent creates a multi-functional formulation where the core ingredients (Ganoderma, Cordyceps sinensis, Radix Panacis Quinquefolii, Radix Et Rhizoma Ginseng) work synergistically to provide multiple therapeutic effects: direct antiviral activity against HIV, immunomodulation to restore CD4+ cell counts, and reduction of oxidative stress. This universal approach addresses multiple aspects of AIDS pathology simultaneously, overcoming the limitations of single-target antiretroviral drugs.
Solution Approach 2:
The formulation is segmented into core ingredients (providing antiviral and immunomodulatory effects) and auxiliary ingredients (enhancing specific functions like anti-inflammatory or antioxidant effects). This segmentation allows flexible adjustment of the formulation to address different clinical presentations and complications of AIDS.
3Adaptability or versatility
If traditional Chinese medicine is explored for AIDS treatment, then effective methods and medicaments can be found, but extensive research and validation are required
Solution Approach 1:
The patent builds upon preliminary research and clinical observations of traditional Chinese medicine ingredients that have demonstrated antiviral and immunomodulatory properties. The formulation incorporates ingredients with known biological activities (e.g., Ganoderma for immun enhancement, Cordyceps for antiviral effects), allowing the development process to leverage existing knowledge rather than starting from scratch.
Solution Approach 2:
The patent uses traditional Chinese medicine theory and modern pharmacological research as intermediaries to bridge traditional herbal knowledge and evidence-based medicine. By selecting ingredients with documented bioactive compounds and mechanisms of action, the formulation connects traditional therapeutic approaches with modern scientific validation methods, accelerating the research and approval process.
Data Source
AI summary
The present invention relates to a pharmaceutical composition made from the following raw materials or from water and/or alcohol extracts of the following raw materials in parts by weight: 5 to 200 parts of Ganoderma, 5 to 150 parts of Radix Panacis Quinquefolii or Radix Et Rhizoma Ginseng, 1 to 90 parts of fermented Cordyceps sinensis powder and/or 1 to 120 parts of Cordyceps, and optionally one or more of 5 to 90 parts of Flos Rosae Rugosae, 5 to 150 parts of Ganoderma spore powder, 10 to 400 parts of Radix Pseudostellariae, 3 to 400 parts of Radix Codonopsis and 3 to 400 parts of Radix Astragali. Clinical trials demonstrate that the composition can significantly reduce HIV virus load in patients, increase the number of CD4+ cells, enhance the immunity of patients, has no considerable toxic and side effects, and is suitable for long-term use.